Cover Image
市場調查報告書

糖尿病神經病變:開發平台分析

Diabetic Neuropathy - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192558
出版日期 內容資訊 英文 117 Pages
訂單完成後即時交付
價格
Back to Top
糖尿病神經病變:開發平台分析 Diabetic Neuropathy - Pipeline Review, H2 2016
出版日期: 2016年11月16日 內容資訊: 英文 117 Pages
簡介

糖尿病神經病變是糖尿病最常見的併發症,是感知疼痛的神經受損,症狀有疼,發麻,灼熱感,疼痛等症狀。致病因子有肥胖、高血壓、高脂質·高血糖、抽煙。可以藥物治療和改善飲食習慣來控制。

本報告提供糖尿病神經病變的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

糖尿病神經病變概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

開發治療藥的企業

  • Achelios Therapeutics, Inc.
  • Araim Pharmaceuticals, Inc.
  • Celgene Corporation
  • Commence Bio, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Glucox Biotech AB
  • Kineta, Inc.
  • Lpath, Inc.
  • Neuralstem, Inc.
  • NovaLead Pharma Pvt. Ltd.
  • Omeros Corporation
  • PhiloGene, Inc.
  • Reata Pharmaceuticals, Inc.
  • Relief Therapeutics S.A.
  • Sucampo Pharmaceuticals, Inc.
  • 大日本住友製藥
  • ViroMed Co., Ltd.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8653IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy - Pipeline Review, H2 2016, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape.

Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning and pain. The predisposing factors are obesity, hypertension, high lipid and sugar levels, smoking, etc. It may be managed by medication and dietary modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Neuropathy - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 1, 1, 16 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.Diabetic Neuropathy.

Diabetic Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Diabetic Neuropathy Overview
  • Therapeutics Development
    • Pipeline Products for Diabetic Neuropathy - Overview
    • Pipeline Products for Diabetic Neuropathy - Comparative Analysis
  • Diabetic Neuropathy - Therapeutics under Development by Companies
  • Diabetic Neuropathy - Therapeutics under Investigation by Universities/Institutes
  • Diabetic Neuropathy - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Diabetic Neuropathy - Products under Development by Companies
  • Diabetic Neuropathy - Products under Investigation by Universities/Institutes
  • Diabetic Neuropathy - Companies Involved in Therapeutics Development
    • Achelios Therapeutics, Inc.
    • Araim Pharmaceuticals, Inc.
    • Celgene Corporation
    • Commence Bio, Inc.
    • Glucox Biotech AB
    • KPI Therapeutics, Inc.
    • Lpath, Inc.
    • Medifron DBT Co., Ltd.
    • Neuralstem, Inc.
    • NovaLead Pharma Pvt. Ltd.
    • Novartis AG
    • Omeros Corporation
    • PhiloGene, Inc.
    • Reata Pharmaceuticals, Inc.
    • Relief Therapeutics S.A.
    • Sucampo Pharmaceuticals, Inc.
    • ViroMed Co Ltd
  • Diabetic Neuropathy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • atexakin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • benfotiamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNV-222 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cibinetide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CMB-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cyndacel-M - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EMA-401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ketoprofen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Lpathomab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MDR-652 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ND-07 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NLP-198 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NSI-189 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NSI-566 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-721 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PDA-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pirenzepine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RTA-901 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RTU-1096 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Diabetic Neuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Hsp90 for Amyotrophic Lateral Sclerosis and Peripheral Neuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • U-2902 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VM-202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XK-568b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Diabetic Neuropathy - Dormant Projects
  • Diabetic Neuropathy - Discontinued Products
  • Diabetic Neuropathy - Product Development Milestones
    • Featured News & Press Releases
      • Sep 08, 2016: ViroMed proceeding with the World's first phase III gene therapy clinical trial for diabetic peripheral neuropathy
      • Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy
      • Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition
      • Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab
      • Sep 12, 2011: Spinifex Pharmaceuticals Presents New Data On EMA401 In Model Of Diabetic Neuropathy At 21st Annual NEURODIAB Meeting
      • Mar 18, 2011: ViroMed Enrolls Final Patient For US VM202-DPN Phase I/II Clinical Trial
      • Mar 04, 2009: ViroMed Receives Approval from US FDA for Phase I/II Trial for Diabetic Neuropathy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Diabetic Neuropathy, H2 2016
  • Number of Products under Development for Diabetic Neuropathy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Diabetic Neuropathy - Pipeline by Achelios Therapeutics, Inc., H2 2016
  • Diabetic Neuropathy - Pipeline by Araim Pharmaceuticals, Inc., H2 2016
  • Diabetic Neuropathy - Pipeline by Celgene Corporation, H2 2016
  • Diabetic Neuropathy - Pipeline by Commence Bio, Inc., H2 2016
  • Diabetic Neuropathy - Pipeline by Glucox Biotech AB, H2 2016
  • Diabetic Neuropathy - Pipeline by KPI Therapeutics, Inc., H2 2016
  • Diabetic Neuropathy - Pipeline by Lpath, Inc., H2 2016
  • Diabetic Neuropathy - Pipeline by Medifron DBT Co., Ltd., H2 2016
  • Diabetic Neuropathy - Pipeline by Neuralstem, Inc., H2 2016
  • Diabetic Neuropathy - Pipeline by NovaLead Pharma Pvt. Ltd., H2 2016
  • Diabetic Neuropathy - Pipeline by Novartis AG, H2 2016
  • Diabetic Neuropathy - Pipeline by Omeros Corporation, H2 2016
  • Diabetic Neuropathy - Pipeline by PhiloGene, Inc., H2 2016
  • Diabetic Neuropathy - Pipeline by Reata Pharmaceuticals, Inc., H2 2016
  • Diabetic Neuropathy - Pipeline by Relief Therapeutics S.A., H2 2016
  • Diabetic Neuropathy - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
  • Diabetic Neuropathy - Pipeline by ViroMed Co Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Diabetic Neuropathy - Dormant Projects, H2 2016
  • Diabetic Neuropathy - Dormant Projects (Contd..1), H2 2016
  • Diabetic Neuropathy - Dormant Projects (Contd..2), H2 2016
  • Diabetic Neuropathy - Dormant Projects (Contd..3), H2 2016
  • Diabetic Neuropathy - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Diabetic Neuropathy, H2 2016
  • Number of Products under Development for Diabetic Neuropathy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top